Haleon Pakistan exports Centrum to Kenya, boosting global outreach

PAKISTAN – Haleon Pakistan Limited, a key subsidiary of British consumer healthcare giant Haleon, has successfully dispatched its first consignment of the globally renowned multivitamin brand Centrum to Kenya.

Manufactured at the company’s Jamshoro facility, this export marks a significant milestone in Haleon Pakistan’s ambitious export expansion strategy for 2025.

It not only highlights the firm’s growing international footprint but also reinforces its commitment to supporting Pakistan’s economy through increased trade and foreign exchange earnings.

The successful shipment of Centrum is a strategic move in Haleon Pakistan’s broader plan to leverage its robust local manufacturing capabilities.

The initiative is expected to open up new trade opportunities, allowing the company to further penetrate international markets.

With an already strong presence in the domestic market, where its flagship products CAC-1000 Plus and Qalsium-D account for Rs7.5 billion (US $26.7 million) in revenue within Pakistan’s Rs24 billion (US $85.5 million) Vitamin Mineral Supplement (VMS) market, this export marks a pivotal step towards capturing a greater market share.

Haleon Pakistan has ambitious plans to secure at least 10% of its sales from exports in the next two years, a notable increase from the 5-6% achieved in 2022.

The role of government support has been crucial in facilitating this export milestone. Haleon Pakistan acknowledged the assistance of relevant authorities and the Special Investment Facilitation Council (SIFC), which played a key role in smoothing the export process.

Such collaborative efforts not only streamline operations for private enterprises but also position Pakistan as a competitive player in the global pharmaceutical and nutraceutical sectors.

In addition to its export achievements, Haleon Pakistan is simultaneously focused on expanding its product portfolio.

CEO Farhan Muhammad Haroon recently outlined plans to diversify the company’s offerings, particularly in the pain management segment. The company intends to introduce Panadol products targeting menstrual pain and migraines next year.

This move is expected to complement its current range of health supplements and further solidify its market position both locally and internationally.

Investment in local manufacturing has been a cornerstone of Haleon Pakistan’s strategy. Last year, the company invested US $10 million to enhance its production capacities, a commitment that has already begun to yield dividends with the launch of Centrum.